Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2021
February 25, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome (MPS-IH)
February 09, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
All eight patients treated with OTL-203 show stable cognitive function, motor function and growth within the normal range at multiple data points post-treatment Supportive initial OTL-201 biomarker...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces $150 Million Strategic Financing
February 05, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it has executed a securities purchase agreement to raise...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer
January 29, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the appointment of Braden Parker to the role of...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Outlines Comprehensive Presence at 2021 WORLDSymposium™
January 28, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
Nine abstracts accepted demonstrating potential of HSC gene therapy to treat multiple neurodegenerative disorders New clinical data from all eight patients treated with OTL-203 for...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Secures Partnerships to Broaden Access to LibmeldyTM for Eligible Patients in Middle East & Turkey
January 19, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced plans to extend the company’s commercial reach in...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD)
January 14, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the U.S. Food and Drug Administration (FDA) has granted...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces 2021 Corporate Priorities Supporting the Build-out of its Commercial Business in Hematopoietic Stem Cell (HSC) Gene Therapy and Expansion of its Clinical Applications
January 11, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
Preparations on Track for First Half 2021 Commercial Launch of Libmeldy™ (OTL-200), the First Approved Product for Metachromatic Leukodystrophy (MLD) in the EU Filing Strategy for OTL-200 Biologics...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the 39th Annual...
ORTX, Telethen, OSR-Tiget
Orchard Therapeutics Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
December 21, 2020 07:00 ET | Orchard Therapeutics (Europe) Limited
First gene therapy to receive full EU marketing authorization for eligible MLD patients One-time treatment with Libmeldy has been shown to preserve motor and cognitive function Achievement shared...